purity comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
åºåˆ—层é¢çš„改动åŒæ—¶è§£å†³äº†ä¸¤ä¸ªé—®é¢˜ï¼Œå³é…¶è§£ç¨³å®šæ€§ä¸Žè‚¾è„清除速度。天然 GLP-1 在循环ä¸çš„åŠè¡°æœŸä»…约两分钟，主è¦è¢«äºŒè‚½åŸºè‚½é…¶-4 迅速ç活。酰化侧链与白蛋白的å¯é€†ç»“åˆå½¢æˆå¾ªçŽ¯å‚¨åº“，使分å缓慢释放并æŒç»æ¿€æ´»å—体。这ç§è®¾è®¡æ€è·¯åŽæ¥è¢«å¹¿æ³›ç”¨äºŽåŒç±»é•¿æ•ˆè‚½çš„å¼€å‘，属于该类è¯ç‰©åŒ–å¦æ”¹é€ 的典型范å¼ã€‚
Semaglutide 是一ç§ç»ç»“æž„ä¿®é¥°çš„èƒ°é«˜è¡€ç³–ç´ æ ·è‚½-1 类似物，其主链与内æºæ€§ GLP-1(7-36) 约有百分之ä¹å四的åºåˆ—一致性。第 8 ä½ä¸™æ°¨é…¸è¢« α-氨基异ä¸é…¸å–代，使二肽基肽酶-4 æ— æ³•è¯†åˆ«åŽŸæœ‰åˆ‡å‰²ä½ç‚¹ã€‚第 34 ä½èµ–氨酸æ¢ä¸ºç²¾æ°¨é…¸ï¼Œè¿›ä¸€æ¥é™ä½Žé…¶è§£é€ŸçŽ‡ã€‚第 26 ä½èµ–氨酸ç»é—´éš”基连接一æ¡å«å八个碳的二酸脂肪链，该侧链赋予分å与血浆白蛋白结åˆçš„能力。
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| 分åå¼ | C187H291N45O59 | 按主链与 C18 二酸侧链计算 |
| 分åé‡ | 约 4113.6 é“尔顿 | 游离碱形å¼ï¼Œéšå离å略有差异 |
| 外观 | 白色至类白色冻干粉末 | å…·å¸æ¹¿æ€§ï¼Œéœ€å¹²ç‡¥ä¿å˜ |
| 溶解性 | 微溶于水，易溶于碱性缓冲液 | æº¶è§£æ€§éš pH å‡é«˜è€Œæ”¹å–„ |
| ç‰ç”µç‚¹ | 约 5.4 | å½±å“缓冲液选择与èšé›†å€¾å‘ |
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
A 2004 essay on the relation between car colour and safety stated that no previous studies had been scientifically conclusive. Since then, a Swedish study found that pink cars are involved in the fewest and black cars are involved in the most crashes (Land transport NZ 2005). In Auckland New Zealand, a study found that there was a significantly lower rate of serious injury in silver cars, with higher rates in brown, black, and green cars. The Vehicle Colour Study, conducted by Monash University Accident Research Centre (MUARC) and published in 2007, analysed 855,258 crashes that occurring between 1987 and 2004 in the Australian states of Victoria and Western Australia that resulted in injury or in a vehicle being towed away. The study analysed risk by light condition. It found that in daylight, black cars were 12% more likely than white to be involved in a collision, followed by grey cars at 11%, silver cars at 10%, and red and blue cars at 7%, with no other colours found to be significantly more or less risky than white. At dawn or dusk, the risk ratio for black cars jumped to 47% more likely than white, and that for silver cars to 15%. In the hours of darkness, only red and silver cars were found to be significantly more risky than white, by 10% and 8% respectively.
Early measurements of coaxial stacking were performed using biochemical assays that studies the relative migration of different nucleic acid molecules based on their conformation and the kind of interactions present. Short DNA molecules containing nicks that could still stack coaxially migrated faster than DNA molecules containing gaps and thus had no coaxial stacking. This could be explained by polymeric properties of DNA where are more rigid rod like molecule will migrate faster along an electrical gradient in a matrix compared to a more flexible molecule. Development of newer techniques such as optical tweezers and the ability to fold DNA nanostructures led to measurement so of DNA bundles and their ability to stack with each other. The force needed to pull these bundles apart using optical tweezers could then be analyzed to measure the base-pair stacking energies. These measurements were performed mainly under non-equilibrium conditions and various extrapolations were made to arrive at the exact values of coaxial stacking between bases. Recent single-molecule studies using DNA nanostructures and DNA-PAINT super-resolution microscopy has allowed for measurement of these interaction between dinucleotides using in-depth kinetic analysis of binding times of short DNA molecules to their complimentary sequences in the presence or absence of DNA-stacking interactions.
6 CO2 + 6 H2O → C6H12O6 + 6 O2 For example, large blooms of plankton (free-floating organisms) absorb large amounts of 12C from the oceans. Originally, the 12C was mostly incorporated into the seawater from the atmosphere. If the oceans that the plankton live in are stratified (meaning that there are layers of warm water near the top, and colder water deeper down), then the surface water does not mix very much with the deeper waters, so that when the plankton dies, it sinks and takes away 12C from the surface, leaving the surface layers relatively rich in 13C. Where cold waters well up from the depths (such as in the North Atlantic), the water carries 12C back up with it; when the ocean was less stratified than today, there was much more 12C in the skeletons of surface-dwelling species. Other indicators of past climate include the presence of tropical species and coral growth rings.
Lactose intolerance is a lessened ability or a complete inability to digest lactose, a sugar found in dairy products. Humans vary in the amount of lactose they can tolerate before symptoms develop. Symptoms may include abdominal pain, bloating, diarrhea, flatulence, and nausea. These symptoms typically start thirty minutes to two hours after eating or drinking something containing lactose, with the severity typically depending on the amount consumed. Lactose intolerance does not cause damage to the gastrointestinal tract. Lactose intolerance is due to the lack of the enzyme lactase in the small intestines to break lactose down into glucose and galactose. There are four types: primary, secondary, developmental, and congenital. Primary lactose intolerance occurs as the amount of lactase declines as people grow up. Secondary lactose intolerance is due to injury to the small intestine. Such injury could be the result of infection, celiac disease, inflammatory bowel disease, or other diseases. Developmental lactose intolerance may occur in premature babies and usually improves over a short period of time. Congenital lactose intolerance is an extremely rare genetic disorder in which little or no lactase is made from birth. The reduction of lactase production starts typically in late childhood or early adulthood, and prevalence increases with age. Diagnosis may be confirmed if symptoms resolve following eliminating lactose from the diet. Other supporting tests include a hydrogen breath test and a stool acidity test.
Sources: en.wikipedia.org
The person's medical history; early chronic pain, a childhood history of pain, an emergence of broad pain following physical or psychosocial stress, a general hypersensitivity to touch, smell, noise, taste, hypervigilance, and various somatic symptoms (gastrointestinal, urology, gynecology, neurology) may signal FM. A physical examination and laboratory investigations may be used to eliminate alternative causes. Common tests that are conducted include complete blood count, comprehensive metabolic panel, erythrocyte sedimentation rate, C-reactive protein, and thyroid function test. Possible misdiagnoses are
== External links == Countercurrent multiplier animation from Colorado University. Research about elephant seals using countercurrent heat exchange to keep heat from leaving their body while breathing out, during hibernation. Patent for a snow mask with a removable countercurrent exchange module which keeps the warmth from leaving the mask when breathing out.
Martinez (1977), 8th Virginia secretary of transportation and deputy administrator of the United States Maritime Administration David Paterson (1977), first African-American governor of New York Karl Dean (1978), mayor of Nashville Christopher Dell (1978), career diplomat, former US ambassador to Zimbabwe, Angola, and Kosovo Martin J. Dunn (1979), former mayor of Holyoke, Massachusetts and member of the Massachusetts Senate Jim McGreevey (1978), 53rd governor of New Jersey Andres Alonso (1979), former CEO of Baltimore City Public Schools Timothy Horrigan (1979), member of the New Hampshire House of Representatives Randal Quarles (1981), 15th under secretary of the treasury for domestic finance, chair of the Financial Stability Board and vice chairman of the Federal Reserve Andrew C. McCarthy (1981), assistant U.S. attorney and columnist for National Review Charles J. O'Byrne (1981), secretary to the governor of New York Michael Waldman (1982), speechwriter for president Clinton; president of the Brennan Center for Justice John Solecki (1982), U.S. official for the United Nations high commissioner for Refugees, kidnapped in Pakistan by the Balochistan Liberation United Front in 2009 Barack Obama (1983), 44th president of the United States and first African-American to hold the office; former senator from Illinois; winner of the 2009 Nobel Peace Prize Victor Cha (1983), foreign policy expert; President Bush's top advisor on North Korean affairs Jay Lefkowitz (1984), George W.
Sources: en.wikipedia.org
== Medical uses == Cipaglucosidase alfa is a long-term enzyme replacement therapy used in combination with the enzyme stabilizer miglustat for the treatment of adults with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency).
A July 2016 study in The Lancet Psychiatry reported that nearly half of transgender people surveyed undertook body-altering procedures without medical supervision. Transition-related care is not covered under Mexico's national health plan. Only one public health institution in Mexico provides free hormones for transgender people. Health care for transgender Mexicans focuses on HIV and prevention of other sexually transmitted diseases. The Lancet study also found that many transgender Mexicans have physical health problems due to living on the margins of society. The authors of the study recommended that the World Health Organization declassify transgender identity as a mental disorder, to reduce stigma against this population. In June 2020, the Mexican federal government released "The Protocol for Access without Discrimination to Health Care Services for Lesbian, Gay, Bisexual, Transsexual, Transvestite, Transgender, and Intersex Persons and Specific Care Guidelines." The guidelines are used in healthcare facilities administered by the government. The guidelines state that the process of identifying one's sexual orientation, gender identify and/or expression can occur at early ages. Thus, the guidelines recommend that medical facilities and doctors consider the use of puberty blockers and cross-sex hormones as a treatment for transgender minors when appropriate. In addition to the guidelines, multiple Mexican states have modified their civil codes to recognize gender-affirming healthcare as a right for transgender people under the age of eighteen.
The triangular teeth can reach 7.5 cm (3.0 in). In juveniles, they are elongated and pointy but become broader and more serrated as they develop into adults. This reflects a shift from a diet mainly of fish to the incorporation of marine mammals. The front teeth are adapted for penetrating prey while the rear teeth, flattened at the sides and bent backwards, are designed for tearing. A total of around 300 teeth are arranged in rows like a conveyor belt, with teeth at the back moving to replace those at the front. The jaws are separate from the skull and are connected to the body entirely by muscles and tendons, allowing them to extend forward. A 2008 study using a computer scan of a 2.5 m (8.2 ft) long and 240 kg (530 lb) juvenile white shark determined that the specimen could exert a bite force of 1,602 newtons (360 lbf) in the front and 3,131 newtons (704 lbf) in the back. From this, the researchers calculated that a specimen 6.4 m (21 ft) long and weighing 3,324 kg (7,328 lb) could exert a bite force of 9,320 newtons (2,100 lbf) in the front and 18,216 newtons (4,095 lbf) in the back. The jaws are strengthened by mineralized cartilage; this is lacking in young white sharks, which have to eat softer food.
Although a single injection of long-acting penicillin or other beta-lactam antibiotic cures the disease and is widely available, and the disease is highly localised, many eradication campaigns ended in complacency and neglect; even in areas where transmission was successfully interrupted, re-introduction from infected areas occurred. Yaws eradication remained a priority in South-East Asia. In 1995, the WHO estimated 460,000 worldwide cases. In the Philippines, yaws stopped being listed as a notifiable disease in 1973; as of 2020, it is still present in the country. India implemented a successful yaws eradication campaign that resulted in the 2016 certification by the WHO that India was free of yaws. In 1996 there were 3,571 yaws cases in India; in 1997 after a serious elimination effort began the number of cases fell to 735. By 2003, the number of cases was 46. The last clinical case in India was reported in 2003 and the last latent case in 2006; certification by the WHO was achieved in 2016. In 2012 the WHO officially targeted yaws for eradication by 2020 following the development of orally administered azithromycin as a treatment, but missed that target. The Morges approach (named after Morges, Switzerland, where a meeting on it was held) involved mass treatment with azithromycin. This was safe, but ran into problems with antibiotic resistance, and did not fully interrupt transmission.
Sources: en.wikipedia.org
差别集ä¸åœ¨ä¸‰å¤„：第 8 ä½æ®‹åŸºè¢«éžå¤©ç„¶æ°¨åŸºé…¸å–代，第 34 ä½æ¢æˆç²¾æ°¨é…¸ï¼Œç¬¬ 26 ä½å¢žåŠ 一æ¡è„‚肪酸侧链。å‰ä¸¤å¤„改动é™ä½Žé…¶è§£é€ŸçŽ‡ï¼Œä¾§é“¾åˆ™é€šè¿‡ç™½è›‹ç™½ç»“åˆå»¶é•¿å¾ªçŽ¯æ—¶é—´ã€‚综åˆç»“果是åŠè¡°æœŸä»Žçº¦ä¸¤åˆ†é’Ÿå»¶é•¿åˆ°çº¦ä¸€å‘¨ã€‚
èƒ°å²›ç´ é‡Šæ”¾éœ€è¦ç»†èƒžå†…环腺苷酸与钙信å·å‡é«˜ï¼ŒåŒæ—¶ä¾èµ–è‘¡è„糖代谢产生的ååŒä¿¡å·ã€‚血糖水平较低时ååŒä¿¡å·ä¸è¶³ï¼Œåˆ†æ³Œå¢žå¼ºæœ‰é™ã€‚这一机制在é™ç³–效果与低血糖风险之间æ供了缓冲。
白蛋白结åˆæ˜¯ä¸»è¦åŽŸå› ，它å‡å°‘肾å°çƒæ»¤è¿‡å¹¶ä¿æŠ¤åˆ†åå…å—蛋白酶é™è§£ã€‚åºåˆ—修饰带æ¥çš„酶解抵抗åŒæ ·ä¸å¯å¿½ç•¥ï¼ŒäºŒè€…å…±åŒä½œç”¨ã€‚脂肪链的ç–水性还会影å“组织分布，但其对总åŠè¡°æœŸçš„贡献程度ä»åœ¨ç ”究之ä¸ã€‚
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.